Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 48 Suppl 1, S38-57

The Challenges in Primary Sclerosing Cholangitis--Aetiopathogenesis, Autoimmunity, Management and Malignancy

Affiliations
Review

The Challenges in Primary Sclerosing Cholangitis--Aetiopathogenesis, Autoimmunity, Management and Malignancy

Tobias J Weismüller et al. J Hepatol.

Abstract

Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease, characterized by progressive inflammation and fibrosis of the bile ducts, resulting in biliary cirrhosis and is associated with a high risk of cholangiocarcinoma. The majority of patients are young, male and have coexisting inflammatory bowel disease. PSC is found with a prevalence of 10/100,000 in Northern European populations. The pathophysiology of PSC is a complex multistep process including immunological mechanisms, immunogenetic susceptibility and disorders of the biliary epithelia. The diagnosis is primarily based on endoscopic cholangiography although magnetic resonance imaging is increasingly used; biochemistry and immunoserology as well as histology play only a minor role. Due to the high risk of developing cholangiocarcinoma and also other tumours of the GI tract, surveillance strategies are essential, however they have yet to be established and evaluated. Biochemical parameters, clinical risk factors, endoscopic procedures and imaging techniques contribute to the early identification of patients at risk. Since medical therapy of PSC with ursodeoxycholic acid does not improve survival, to date, liver transplantation is the only option with a cure potential; if transplantation is accurately timed, transplanted PSC patients have an excellent rate of survival. However if cholangiocarcinoma is detected, a curative treatment is not possible in the majority of cases. The present review critically summarizes the current knowledge on the aetiopathogenesis of PSC and gives an overview of the diagnostic approaches, surveillance strategies and therapeutic options. Primary sclerosing cholangitis is a disease of unknown aetiology and without any further curative treatment options apart from liver transplantation. Therefore it may be regarded as the greatest challenge in hepatology today.

Comment in

Similar articles

  • Immunogenetic Aspects of Primary Sclerosing Cholangitis: Implications for Therapeutic Strategies
    AW van Milligen de Wit et al. Am J Gastroenterol 90 (6), 893-900. PMID 7771416. - Review
    Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterized by fibro-obliterative inflammation of the intra- and extrahepatic bile ducts; in …
  • Primary Sclerosing Cholangitis and Cholangiocarcinoma
    KN Lazaridis et al. Semin Liver Dis 26 (1), 42-51. PMID 16496232. - Review
    Primary sclerosing cholangitis (PSC), a cholestatic liver disease characterized by fibrosing inflammatory damage of the biliary tree, is a risk factor for cholangiocarcin …
  • Management of Primary Sclerosing Cholangitis
    E Björnsson. Minerva Gastroenterol Dietol 55 (2), 163-72. PMID 19305376. - Review
    Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease with fibrosis surrounding the intrahepatic and/or the extrahepatic bile ducts. PSC is characte …
  • Primary Sclerosing Cholangitis
    HJ Rodriguez et al. Semin Gastrointest Dis 14 (4), 189-98. PMID 14719769. - Review
    Primary sclerosing cholangitis (PSC) is an idiopathic, chronic cholestatic liver disease of uncertain etiopathogenesis commonly associated with inflammatory bowel disease …
  • Sclerosing Cholangitis
    GR MacFaul et al. Curr Opin Gastroenterol 22 (3), 288-93. PMID 16550044. - Review
    It is likely that a number of patients previously diagnosed with primary sclerosing cholangitis have autoimmune pancreatitis in association with primary sclerosing cholan …
See all similar articles

Cited by 41 PubMed Central articles

See all "Cited by" articles

Publication types

MeSH terms

LinkOut - more resources

Feedback